Enalapril Worldwide Experience
- 1 August 1984
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 77 (2) , 23-35
- https://doi.org/10.1016/s0002-9343(84)80055-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): A new angiotensin-converting enzyme inhibitorMetabolism, 1983
- Altered Fractional Tetrahydroaldosterone Excretion during Pharmacological Blockade and Activation of the Renin-Aldosterone System*Journal of Clinical Endocrinology & Metabolism, 1982
- Antihypertensive Therapy with MK 4211Journal of Cardiovascular Pharmacology, 1982
- Effects of enalapril, a new converting enzyme inhibitor, in hypertensionClinical Pharmacology & Therapeutics, 1982
- Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive ratsEuropean Journal of Pharmacology, 1981
- ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".The Lancet, 1981
- Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.BMJ, 1981
- Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.British Journal of Clinical Pharmacology, 1981
- A new class of angiotensin-converting enzyme inhibitorsNature, 1980
- Disposition of captopril in normal subjectsClinical Pharmacology & Therapeutics, 1980